DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: behavioral dietary intervention
Dietary Supplement: dietary intervention
Procedure: therapeutic dietary intervention

First Posted Date: 2004-05-19

Last Posted Date: 2018-11-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00082732

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2

Active, not recruiting

Conditions: Urethral Cancer
Urachal Cancer
Bladder Cancer

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: Leucovorin
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2004-05-19

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00082706

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Phase 1

Completed

Conditions: Urethral Cancer
Bladder Cancer

Interventions: Biological: Recombinant Interferon Alfa

First Posted Date: 2004-05-19

Last Posted Date: 2015-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00082719

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Fludarabine Phosphate
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-05-03

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00004246

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: Recombinant Interferon Alfa
Drug: Cytarabine
Drug: Omacetaxine Mepesuccinate

First Posted Date: 2004-04-30

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00003239

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Chemotherapy
Drug: Tretinoin Liposome

First Posted Date: 2004-04-28

Last Posted Date: 2012-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00005969

Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Clofarabine

First Posted Date: 2004-04-27

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT00081887

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Avastin
Drug: Rituximab

First Posted Date: 2004-04-27

Last Posted Date: 2012-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00081861

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Myelofibrosis
Leukemia
Mantle Cell Lymphoma

Interventions: Drug: RAD001

First Posted Date: 2004-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00081874

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: Cyclophosphamide
Drug: Psoralen
Drug: Thiotepa
Procedure: Allogeneic bone marrow transplantation
Procedure: In vitro-treated peripheral blood stem cell transplantation (PBSCT)
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-04-23

Last Posted Date: 2018-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00005092

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy